by Raynovich Rod | Jan 22, 2013 | BIOgraph, Biopharmaceuticals, Life Science ETF's and Mutual Funds
Bullish Mentality Drives Usual MO-vers: PCYC, MDVN, REGN, SGEN It is hard to add biotech stocks to your portfolio at these elevated levels but big players like Fidelity, Cap World, JPMorgan, T.Rowe Price and selected hedge funds- Orbimed, Baker Bros, etc can drive...
by Raynovich Rod | Jan 16, 2013 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
A double top in the biotechnology sector could be developing although many mid and small cap stocks are in the green. We are still at or near the October highs in the sector but the seasonality effect is waning (strong November -January performance). Moreover many of...
by Raynovich Rod | Jan 16, 2013 | BIOgraph, Life Science ETF's and Mutual Funds
Biotech ETF’s Slightly Outperform Life Science Mutual Funds There has been an ongoing debate in the media on the performance of ETFs compared to actively managed funds so we have compared the performance in a hot sector like biotech which is entering its 5th...
by Raynovich Rod | Sep 26, 2012 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
Is There No End to the Biotech Bull Market? Biotech ETFs NASDAQ Biotechnology (IBB) up 36% YTD and NYSE (FBT) up 42% YTD Around 1998 I remember vividly two market conversations: one from a Sun Micro sales executive telling me “there is no end to chip...
by Raynovich Rod | Sep 25, 2012 | 2024-25 Life Science Portfolios, BIOgraph
Biotech Stocks Remain Resilient On A Bad Day The market took a nasty turn today with a 1.36% sell-off in NASDAQ and 1.05% for the S&P. The damage was across the board but the healthcare sector rose above the flack down only 0.11%. Large cap drug and...
by Raynovich Rod | Aug 16, 2012 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph, Life Science ETF's and Mutual Funds
QQQs Outperforming Biotech ETFs IBB and XBI-Take a Little Off Biotech Stocks are weak again today with both ETFs showing distribution and momentum moving toward the bottom of the channel. Nothing major but 3-5% off July tops. The QQQs continue to outperform today up...
by Raynovich Rod | May 16, 2012 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph, Life Science ETF's and Mutual Funds
Why is the biotechnology sector still strong? Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs. Bellwether ETFs IBB (126) and XBI ($82.85) are up over 20% YTD after a brief...
by Raynovich Rod | May 9, 2012 | 2024-25 Life Science Portfolios, Biopharmaceuticals, Clinical Diagnostics and Tools, Life Science ETF's and Mutual Funds
Market Off Its Lows Today-Consumer Cyclical and Technology Outperforming Healthcare The market continues to be weak with the NASDAQ entering its 5th day of the sell-off down 4.29% but the QQQ ($64.29) NASDAQ-100 has recovered from lows today. The ETF IBB ($64.32) has...
by Raynovich Rod | Jan 25, 2012 | 2024-25 Life Science Portfolios, BIOgraph, Clinical Diagnostics and Tools
M&A Theme Provides Underlying Bid to Market Roche Holding, the most diversified diagnostics and pharmaceutical Company with an aggressive leveraged strategy for the molecular basis of disease and personalized medicine has offered $5.7B for the leading Company in...
by Raynovich Rod | Nov 21, 2011 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph, Life Science ETF's and Mutual Funds
Pharmasset Buyout Brings To Mind M&A Upside for Biotech Stocks: ETF’s and Funds Lead the Way Gilead (GILD $35) stepped up with a huge buyout of Pharmasset (VRUS $134.21) driving the stock up 89% over Fridays’ close and 519% YTD! Pharmasset has no...
